# Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

> **NCT04193176** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 376 (actual)

## Conditions studied

- Chronic Cough

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04193176
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-10
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-09-02
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193176, "Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04193176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*